Open Access

ARTICLE

Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

Xiuhua Weng^*1, Shaohong Luo^*1, Shen Lin^*, Lixian Zhong^†, Meiyue Li^*, Rao Xin^*, Pinfang Huang^*, Xiongwei Xu^*

* Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Taijiang, Fuzhou, P.R. China
† College of Pharmacy, Texas A&M University, College Station, TX, USA